Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-STEAP1 CAR T cells

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) six transmembrane epithelial antigen of the prostate 1 (STEAP1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-STEAP1 CAR T cells recognize and bind to STEAP1-expressing tumor cells, thereby inducing selective toxicity in STEAP1-expressing tumor cells. STEAP1 is overexpressed in a variety of cancer cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-STEAP1 CAR-T cells STEAP1 CAR-T cells STEAP1-targeting CAR T cells STEAP1-targeting CAR-T cells

anti-STEAP1 CAR T cells

Search NCI's Drug Dictionary